Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MHV370 in Sjögren's Syndrome and Mixed Connective Tissue Disease
CTR20220130Phase 2Terminated
- Sponsor
- Novartis
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MHV370 in Sjögren's syndrome, mixed connective tissue disease (MCTD), sponsored by Novartis. Started Feb 2022; status: terminated.
02
Drugs
MHV370
03
Conditions
Sjögren's syndromemixed connective tissue disease (MCTD)
Beyond the preview
Go deeper on CTR20220130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220130.